

<b>ASRS 2026 Annual Meeting</b>			
<b>Wednesday, July 15</b>			
<b>Continental Breakfast</b>		<b>7:15 AM</b>	<b>8:15 AM</b>
<b>Retina Around the Globe (No CME)</b>	Moderators: RV Paul Chan, MD, MSc, MBA and Mrinali Gupta, MD, FASRS; Rajeev Muni, MD, MSc, FRCS(C), FASRS and Nimesh Patel, MD, FASRS; Jorge Fortun, MD and Aleksandra Rachitskaya, MD, FASRS	<b>8:00 AM</b>	<b>11:00 AM</b>
<b>Circus of Complications (No CME)</b>	Moderators: Brian Do, MD, FASRS; Priya Vakharia, MD, FASRS	<b>11:00 AM</b>	<b>12:15 PM</b>
General Lunch + International Lunch; Exhibits Open	Presenters: Masaki Fukushima, MD; Edward Korot, MD; Gregory Lee, MD; Tamara Lenis, MD, PhD; Matthew Trese, DO, MA; Malek Yassine, MD; Sarwar Zahid, MD, FASRS	<b>12:15 PM</b>	<b>1:30 PM</b>
<b>Medical Case Conference</b>	Moderators: Ines Lains, MD, PhD; Anat Loewenstein, MD	<b>1:30 PM</b>	<b>3:00 PM</b>
	Presenters: Mohamed Al Bahiti, MBBS, FRCS; Parnian Arjmand, MD, MSc, FRCS, DABO; Poornachandra B, MS, FVRS; Kevin Blinder, MD, FASRS; Victor Chen, MD; Talisa de Carlo Forest, MD; Ravi Keshavamurthy, MBBS, MD; Ricardo Leal Rodriguez, MD; Sun Young (Sunny) Lee, MD, PhD, FASRS, FARVO; Yasha Modi, MD; Nader Moinfar, MD, MPH, FACS, FASRS; Samir Patel, MD; Sriharanathan Poopalaratnam, MD, FRCS; Emil Anthony Say, MD; Kotaro Tsuboi, MD; Eduardo Uchiyama, MD, FACS	<b>3:00 PM</b>	<b>3:40 PM</b>
Break		<b>3:00 PM</b>	<b>3:40 PM</b>
<b>Surgical Case Conference</b>	Moderators: Carl Awh, MD, FASRS; Caroline Awh, MD	<b>3:40 PM</b>	<b>5:10 PM</b>
	Presenters: Luis Acaba-Berrocal, MD; Sulaiman Al Sulaiman, MD; Alay Banker, MD; Mauricio Bayram-Suverza, MD; Yodpong Chantarasorn, MD; Jordan Deaner, MD; Charles DeBoer, MD, PhD; Masaki Fukushima, MD, PhD; Raymond Iezzi, MD, MS; Srinivas Joshi, MD, FASRS; Boonkit Purt, MD, FACS; Padmaja Rani, M.S, FICO, FRCS; Mary-Grace Reeves, MD, MBA; Geovanni Rios, PhD, MD; Pukhraj Rishi, MBBS, MS, DO, FRCS, FRCSEd, FASRS, FACS; Ahmed Sallam, MD PhD FRCOphth; Homayoun Tabandeh, MD, FASRS; Christina Weng, MD, MBA, FASRS		
Opening Reception: Grand Quai Pavilion		<b>6:00 PM</b>	
<b>Thursday, July 16</b>			
<b>Experience Center (Fellows &amp; Residents)</b>		<b>6:30 AM</b>	<b>7:30 AM</b>
<b>Continental Breakfast</b>		<b>7:15 AM</b>	<b>8:15 AM</b>
<b>Opening Comments</b>		<b>8:00 AM</b>	<b>8:05 AM</b>
<b>Welcome to Montreal</b>		<b>8:05 AM</b>	<b>8:10 AM</b>
<b>AMD - Neovascular Panel. Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD</b>		<b>8:10 AM</b>	<b>8:45 AM</b>
One-year, First-in-Human, Safety and Efficacy Data for Subretinal NG101 - a Novel Low-dose AAV Gene Therapy for Wet AMD: A Phase 1/2a Clinical Trial	Peter Kertes, MD, FRCS(C)		
Ixoberogene soroparvovec (Ixo-vec) intravitreal gene therapy for neovascular age-related macular degeneration (nAMD): LUNA trial 2-year results	Shawn Kavoussi, MD		
Ixoberogene soroparvovec intravitreal gene therapy for neovascular age-related macular degeneration: Long-term results from the OPTIC trial	Szilard Kiss, MD, FASRS		
Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3 SOL-1 Trial	Dilsher Dhoot, MD		
Results of a Randomized, Proof-of-Concept Clinical Trial Comparing OLN324 with Faricimab in Patients with Neovascular Age-Related Macular Degeneration	David Eichenbaum, MD, FASRS		
Efficacy and safety of aflibercept 8 mg in previously treated patients with nAMD or DME: 24-week results from the phase 3b ELARA trial	Eric Schneider, MD		
Discussion			
Transition		<b>8:45 AM</b>	<b>8:47 AM</b>
<b>Real-World Symposium 1. Real-World nAMD: Utilization, Outcomes, and Long-Term Anti-VEGF Data</b>		<b>8:47 AM</b>	<b>9:11 AM</b>
Utilization and Trends in Anti-Angiogenic and Anti-Complement Therapeutics from 2023-2025	Anton Kolomeyer, MD, PhD	<b>8:47 AM</b>	<b>8:50 AM</b>
Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database	Andrew Moshfeghi, MD, MBA, FASRS	<b>8:50 AM</b>	<b>8:53 AM</b>
Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: First Time 4.5 Year Results of the TRUCKEE Study	Carl Danzig, MD	<b>8:53 AM</b>	<b>8:56 AM</b>
Long-Term Effectiveness and Safety of Faricimab in Eyes With nAMD: 2-Year Results From the UK FARWIDE Study	Ian Pearce, MB ChB BSc FRCOPHTH	<b>8:56 AM</b>	<b>8:59 AM</b>
Discussion		<b>8:59 AM</b>	<b>9:11 AM</b>
Transition		<b>9:11 AM</b>	<b>9:13 AM</b>
<b>Surgical Techniques and Maneuvers Panel. Mastering Scleral Fixation: Techniques, Pearls, and Pitfalls</b>		<b>9:13 AM</b>	<b>9:43 AM</b>
A NOVEL MODIFIED FLAPLESS SURGICAL TECHNIQUE FOR SUTURELESS SCLERAL FIXATION OF FIL SF INTRAOCULAR LENS: A PROSPECTIVE STUDY	Danilo Iannetta, MD, PhD		
Closed-Globe Internal Refixation of Dislocated PMMA Scleral-Fixated IOLs Using a Modified Double-Flanged Polypropylene Technique: A prospective interventional study	Srinivas Joshi, MD, FASRS		
Sutureless Flanged Versus Gore-Tex for Secondary IOL Implantation: A Comparative Analysis of Surgical Philosophy, Biomechanics, and Clinical Outc	Matias Iglicki, MD		
Lens Tilt and Dislocation After Modified Yamane Fixation: Association With Prophylactic Laser to the Optic-Haptic Junction	Harris Sultan, MS, MD		
Platform Matters? - Comparative Effectiveness of Five Vitrectomy Systems in 1,082 Primary Vitreoretinal Surgeries	Obuli Nandhakumar, MD, MRCS, AMPH		
Discussion			

Break		9:43 AM	10:23 AM
<b>AMD - Neovascular Symposium 1. Rethinking nAMD Care: Home OCT, Treatment Burden, and Real-World Barriers</b>		10:23 AM	10:47 AM
Longitudinal Performance of a Trend Analysis Algorithm for Home OCT Monitoring in Neovascular Age-related Macular Degeneration (NVAMD)	Anat Loewenstein, MD	10:23 AM	10:26 AM
Macular Ganglion Cell Layer Stability After Repeated Anti-VEGF Therapy in Eyes With and Without Primary Open-Angle Glaucoma	Marco Rovati	10:26 AM	10:29 AM
Economic Evaluation of Home OCT: Determinants of Cost-Sparing Potential, Patient Selection, and Clinical Burden	Sean Berkowitz, MD, MBA	10:29 AM	10:32 AM
Impact of Treatment Delays Due to Prior Authorization on Short-term Visual Acuity in Neovascular Age-Related Macular Degeneration	Mingyi Huang, MD	10:32 AM	10:35 AM
Discussion		10:35 AM	10:47 AM
Transition		10:47 AM	10:49 AM
<b>Imaging - Digital - Angiography Symposium. Innovations in Retinal Angiography and Functional Imaging</b>		10:49 AM	11:08 AM
Optoretinography (ORG) for Macular Dysfunction	Kareem Moussa, MD	10:49 AM	10:52 AM
Diagnostic accuracy and sensitivity of ultra-widefield steering-based imaging to detect peripheral retinal breaks	Kevin Blinder, MD, FASRS	10:52 AM	10:55 AM
Synergistic Visions - OCT Angiography and Dynamic Adaptive Optics Angiography for Clinical Assessment of Retinal Microvasculopathy	Richard Rosen, MD, DSc(Hon), FACS, FASRS, FARVO	10:55 AM	10:58 AM
Discussion		10:58 AM	11:08 AM
Transition		11:08 AM	11:10 AM
<b>Complications of Anterior Segment Surgery Panel. When Things Go Wrong: Complications and Decision-Making in Secondary IOL Surgery</b>		11:10 AM	11:35 AM
Comparative Outcomes of Secondary Intraocular Lens Fixation Techniques: Retrospective Analysis of 935 case	Bryon McKay, MD, PhD, FRCSC, DRCPSC - Retina		
Is 20/20 Vision Good Enough? Outcomes of Complete Pars Plana Vitrectomy During IOL Exchange for Lens Opacification in Patients with Preserved Visual Acuity	Steve Levasseur, MD		
Scleral-Suture Secondary Intraocular Lens Implantation Using a Modified Scleral Mesh (Hash-Tag) Technique: Case Series	Carmen Negrin-Martin, MD		
Structural and Functional Outcomes and Recovery Spectrum in Intracameral Cefuroxime Ocular Toxic Syndrome (ICOTS) in Eyes with Disrupted Intraocular Barrier	Andrea Cusumano, MD		
Discussion			
Transition		11:35 AM	11:37 AM
<b>Awards Ceremony</b>		11:37 AM	12:14 PM
Pyron Award Introduction	Geoffrey G. Emerson, MD, PhD, FASRS	11:37 AM	11:39 AM
Pyron Award: Title TBD	Glenn Jaffe, MD	11:39 AM	11:44 AM
Founders Award Introduction	Audina Berrocal, MD, FASRS	11:44 AM	11:46 AM
Founders Award: Title TBD	Carl Awh, MD, FASRS	11:46 AM	11:51 AM
Young Investigator Award Introduction	J. Michael Jumper, MD, FASRS	11:51 AM	11:53 AM
Young Investigator Award: The Retina Mosaic	Yoshihiro Yonekawa, MD, FASRS	11:53 AM	11:58 AM
Packo Award Presentation to Joel Pearlman, MD, PhD	Geoffrey G. Emerson, MD, PhD, FASRS	11:58 AM	12:00 PM
Crystle Apple Award Presentation to Herbert Culver Boldt, MD	ECS co-Chairs	12:00 PM	12:02 PM
WinR Champion Award		12:02 PM	12:04 PM
Tribute Giving	J. Michael Jumper, MD, FASRS	12:04 PM	12:06 PM
2026 M. Gilbert Grand ASRS Vitreoretinal Fellowship Award		12:06 PM	12:08 PM
Retina Image Bank Image of the Year	Manish Nagpal, MD, MD, FRCS (UK), FASRS and Suber S. Huang, MD, MBA, FASRS	12:08 PM	12:09 PM
Retina Atlas Chapter of the Year	Retina Atlas Editors	12:09 PM	12:10 PM
Retina Hall of Fame Award		12:10 PM	12:12 PM
Transition		12:12 PM	12:14 PM
General Lunch + ECS Lunch		12:14 PM	1:29 PM
<b>Business Meeting</b>		1:29 PM	1:44 PM
Transition		1:44 PM	1:46 PM
<b>AMD - Non-neovascular Symposium 1. Beyond Atrophy: Restoring Vision and Redefining Care in Geographic Atrophy</b>		1:46 PM	2:10 PM
Vision Improvement with Sonporetigene Isteparovec Optogenetic Therapy in Macular Degeneration: First Direct-to-Phase 2 Randomized, Controlled Trial	Jordi Mones, MD PhD	1:46 PM	1:49 PM
From Optical Modelling to First-in-Human Add-On Implantation of the SING IMT™: Translational Feasibility of Dual-Lens Intraocular Systems for Late-Stage AMD	Stanislao Rizzo, MD	1:49 PM	1:52 PM
Liquid Biopsy Proteomics: Deciphering the Molecular Mechanisms Behind Increased Neovascular AMD Risk After Anti-complement Therapy in Geographic Atrophy	Tsai-Chu Yeh, MD, MTM	1:52 PM	1:55 PM
Artificial Intelligence in GA: Learnings from the Pegcetacoplan Clinical Program	Paul Hahn, MD, PhD, FASRS	1:55 PM	1:58 PM
Discussion		1:58 PM	2:10 PM
Transition		2:10 PM	2:12 PM

<b>Diabetic Retinopathy Panel 1. Advancing Durability in Diabetic Retinopathy: New Therapies and Long-Term Data</b>		2:12 PM	2:42 PM
Long-Term Effectiveness and Safety of Faricimab in Eyes With DME: 2-Year Results From the UK FARWIDE Study	Sobha Sivaprasad, FRCOphth		
Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time, Primary Endpoint Results from the Phase 3 GLOW2 Trial	Charles Wykoff, MD, PhD, FASRS		
Pagoda Trial Results Through Year 4: Port Delivery Platform With Ranibizumab for the Treatment of Diabetic Macular Edema	Luke Lindsell, OD, MD		
Results of a Randomized, Proof-of-Concept Clinical Trial Comparing OLN324 with Faricimab in Patients with Diabetic Macular Edema	Veeral Sheth, MD, MBA, FASRS, FACS		
Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time Cross-trial Evaluation of the GLOW and GLOW2 Phase 3 Trials	David Brown, MD		
Discussion			
Break		2:42 PM	3:22 PM
<b>Real-World Symposium 2. Managing Macular Edema in the Real World: What the Data Shows</b>		3:22 PM	3:46 PM
Two-Year Real-World Outcomes of Faricimab for Diabetic Macular Edema: Updated Results from the US FARETINA-DME Expanded 2 year cohort in the IRIS <sup>®</sup> Registry	Murtaza Adam, MD	3:22 PM	3:25 PM
Real-World Use of Aflibercept 8 mg in Eyes with Diabetic Macular Edema (DME): Analysis of the IRIS <sup>®</sup> Registry (ILLUMIN-8 6-mo)	Michael Klufas, MD	3:25 PM	3:28 PM
Durability and safety of suprachoroidal triamcinolone acetone in eyes with chronic cystoid macular edema in real-world clinical practice	Sunir Garg, MD, FACS, FASRS	3:28 PM	3:31 PM
Real-World Clinical Outcomes in Patients With Retinal Vein Occlusion With Macular Edema Treated With Faricimab in the Academy IRIS <sup>®</sup> Registry	Rishi Singh, MD	3:31 PM	3:34 PM
Discussion		3:34 PM	3:46 PM
Transition		3:46 PM	3:48 PM
<b>Macular Holes &amp; Macular Pucker Panel 1. Beyond the ILM Flap: Advanced Techniques for Complex Macular Holes</b>		3:48 PM	4:13 PM
Impact of Phacoemulsification on Vitreomacular Traction Release and Complications	Ananth Sastry, MD		
Beyond the Inverted Flap: Clinical utility of a non-inverted ILM free flap and SPOT technique for primary and refractory Macular Holes	Peiquan Zhao, MD		
Predictors of Anatomic and Functional Success with Amniotic Membrane Grafting for Complex Macular Holes	Scott Walter, MD, MSc, FASRS		
Distal ILM Flap for Extra-large, XX-large, and Giant Macular Holes	Homayoun Tabandeh, MD, FASRS		
Discussion			
Transition		4:13 PM	4:15 PM
<b>Technology: Updates in Artificial Intelligence (AI), Augmented Reality, and Robotics. AI in Retina: From Prediction to Clinical and Surgical Decision-Making</b>		4:15 PM	4:39 PM
Prospective Evaluation of AI-Assisted Screening for Clinical Trials in a Real World Setting	Louis Cai, MD	4:15 PM	4:18 PM
Predicting Anti-VEGF Treatment Response in Diabetic Macular Edema Using Automated OCT Biomarkers	Peter Clark, MD	4:18 PM	4:21 PM
OCT-F: An AI-Enabled Tool to Determine Retinal Function from OCT	Srinivas Satta, MD	4:21 PM	4:24 PM
The Digital Surgical Cockpit: Transitioning from Qualitative Visualization to Quantitative Decision Support in Subretinal Gene Therapy	Michael Singer, MD	4:24 PM	4:27 PM
Discussion		4:27 PM	4:39 PM
Transition		4:39 PM	4:41 PM
<b>Macular Holes &amp; Macular Pucker Symposium. Beyond the ILM Flap: Advanced Techniques for Complex Macular Holes</b>		4:41 PM	5:05 PM
Redefining Anatomic Success After Vitrectomy for Lamellar Macular Hole (LMH): Clinical Impact of Persistent or Recurrent LMH and Progression to Full-Thickness Macular Hole	Masaki Fukushima, MD	4:41 PM	4:44 PM
Spontaneous Progression from Lamellar Macular Hole to Full-Thickness Macular Hole: Timing, Characteristics, and Surgical Outcomes	Kotaro Tsuboi, MD	4:44 PM	4:47 PM
Postoperative stages of macular hole recovery through transfluid optical coherence tomography: a comparison between minimal gas vitrectomy and fluid-gas exchange	Yodpong Chantarasorn, MD	4:47 PM	4:50 PM
Early Epiretinal Membrane Surgery Is Associated With Improved Visual Outcomes After Macula-On Retinal Detachment: A Large Database Study	Paul de Bustros, MD, MS	4:50 PM	4:53 PM
Discussion		4:53 PM	5:05 PM
Transition		5:05 PM	5:10 PM
<b>Scientific Poster Q&amp;A and Exhibit Hall Reception</b>		5:10 PM	6:10 PM
Award Winner Dinner at Jatoba			
<b>Friday, July 17</b>			
JVRD breakfast			
<b>Experience Center (Fellows &amp; Residents)</b>		6:30 AM	7:30 AM
Continental Breakfast		7:15 AM	8:15 AM
<b>AMD - Neovascular Symposium 2. Innovations in nAMD: New Targets, New Therapies, Early Results</b>		8:00 AM	8:19 AM
First-in-Human Evaluation of TH103, a Novel Dual-Targeting VEGF/HSPG Biologic: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD	Joel Pearlman, MD, PhD	8:00 AM	8:03 AM
Efficacy and Safety of a Novel Topical Peptide (CG-P5) for the Treatment of Neovascular Age-Related Macular Degeneration: Phase 1 Results	David Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS	8:03 AM	8:06 AM
Randomized, Controlled, Double-Masked Study to Evaluate the Antimicrobial Efficacy of IRX-101: STERILE Trial Results	STEPHEN SMITH, MD	8:06 AM	8:09 AM

Discussion		8:09 AM	8:19 AM
<i>Transition</i>		8:19 AM	8:21 AM
<b>AMD - Non-neovascular Symposium 2. Emerging Therapies in Geographic Atrophy: Gene Therapy, RNA, and Novel Pathways</b>		8:21 AM	8:45 AM
Subretinal Novel Modifier Gene Therapy (OCU410) for Geographic Atrophy: First-Time 1 year Results from the Phase 2 ArMaDa Trial.	Arshad Khanani, MD, MA, FASRS	8:21 AM	8:24 AM
Phase 1/2 Evaluation of OCU410 Novel Modifier Gene Therapy for Geographic Atrophy and Stargardt Disease: Quantitative FAF and SD-OCT Lesion Analysis and Safety Outcomes	Jay Chhablani	8:24 AM	8:27 AM
Phase 1 results of APL-3007: A novel systemic C3 siRNA for geographic atrophy secondary to AMD	Mathew MacCumber, MD, PhD	8:27 AM	8:30 AM
A Phase 2 Clinical Trial of the Inflammasome Inhibitor K8 in Bilateral Geographic Atrophy (GA)	Jayakrishna Ambati, MD	8:30 AM	8:33 AM
Discussion		8:33 AM	8:45 AM
<i>Transition</i>		8:45 AM	8:47 AM
<b>Closing the Gap: Translating Emerging Therapies into Real-World Outcomes in GA</b>		8:47 AM	9:11 AM
Outcomes in Geographic Atrophy: Real-World Evidence from EHR Data and AI-Based Imaging in Patients Treated with Pegcetacoplan	Nimesh Patel, MD, FASRS	8:47 AM	8:50 AM
Earlier treatment yields better outcomes: 5 years of pegcetacoplan treatment for geographic atrophy secondary to AMD	Esther Kim, MD	8:50 AM	8:53 AM
Real-World Utilization, Retention, Safety, and Outcomes of Pegcetacoplan Therapy for Geographic Atrophy in Patients with Follow-up of Two Years	Alexander Miller, MD	8:53 AM	8:56 AM
Assessment of Geographic Atrophy Progression Following Pegcetacoplan in the Real-world With and Without Neovascular Age-related Macular Degeneration	Hasenin Al-khersan, MD	8:56 AM	8:59 AM
Discussion		8:59 AM	9:11 AM
<i>Transition</i>		9:11 AM	9:13 AM
<b>Inflammatory and Infectious Diseases Symposium. Uveitis and Ocular Infection: Evolving Diagnosis and Treatment Strategies</b>		9:13 AM	9:54 AM
Safety of Anti-VEGF Injections in Patients with Uveitis	Mitchell Allphin, MD	9:13 AM	9:16 AM
with infectious retinitis subsequently developing cystoid	Sruthi Arepalli, MD	9:16 AM	9:19 AM
Practice Patterns: Laboratory Support in the Era of 2024 CDC	Mark Breazzano, MD, FACS	9:19 AM	9:22 AM
Discussion		9:22 AM	9:32 AM
Disease-Modifying Strategies in Autoimmune Retinopathy	Majda Hadziahmetovic, MD	9:32 AM	9:35 AM
Long-Term Outcomes of Pediatric Vogt-Koyanagi-Harada Disease	Sulaiman Al Sulaiman, MD	9:35 AM	9:38 AM
associated with contaminated trypan blue use during cataract	Makoto Inoue, MD, FASRS	9:38 AM	9:41 AM
Dynamics and Biodistribution after Suprachoroidal	Glenn Yiu, MD, PhD	9:41 AM	9:44 AM
Discussion		9:44 AM	9:54 AM
<i>Transition</i>		9:54 AM	9:56 AM
<b>Trauma &amp; PVR Symposium. Decision-Making, Surgical Strategies, and Case-Based Insights</b>		9:56 AM	10:05 AM
Objective Ocular Trauma Score (oOTS): A Visual Acuity-Independent Model With Discrimination Comparable to OTS	Shulamit Schwartz, MD	9:56 AM	9:59 AM
tPA-Assistant Trauma Surgery	Adiel Barak, MD	9:59 AM	10:02 AM
Outcomes of Complex PVR Retinal Detachment Repair with and without Intravitreal Methotrexate at a Single Tertiary Care Center	John Miller, MD	10:02 AM	10:05 AM
Break		10:05 AM	10:45 AM
<b>Hereditary Retinal Disease &amp; Genetics Symposium. Emerging Therapeutic and Diagnostic Advances in Inherited Retinal Diseases</b>		10:45 AM	11:09 AM
Perivascular astrocytic gliosis induced by retinal gene therapy for choroideremia	Robert MacLaren, DSc DPhil FRCS FRCOphth FACS FMedSci	10:45 AM	10:48 AM
Intravitreal RNA Therapy for PRPF31-Associated Retinitis Pigmentosa: Results from a Phase 1b Multiple Ascending Dose Study of VP-001	Robert Bhisitkul, MD, PhD	10:48 AM	10:51 AM
Subretinal laru-zova Gene Therapy for XLRP: Preliminary Safety, Efficacy and Surgical Technique in the Phase 2 Multicenter DAWN Trial	Robert Sisk, MD, FACS, FASRS	10:51 AM	10:54 AM
Enhancing Molecular Diagnostic Accuracy in Inherited Retinal Dystrophies Through a Personalized Re-Evaluation Strategy	João Pedro Marques, MD, MSc, PhD, FEBOphth	10:54 AM	10:57 AM
Discussion		10:57 AM	11:09 AM
<i>Transition</i>		11:09 AM	11:11 AM
<b>Diabetic Retinopathy Symposium. Innovations in Diabetic Retinopathy: New Therapies, Delivery Systems, and Disease Biology</b>		11:11 AM	11:41 AM
Oral Tonabersat Connexin-43 Modulator for Diabetic Macular Edema with Good Vision (DRCR Protocol AN)	Andrew Barkmeier, MD	11:11 AM	11:14 AM
Sustained-release PER-001 Intravitreal Implant: Structural and Visual Function Improvements in Patients with Diabetic Retinopathy	Saradha Chexal, MD	11:14 AM	11:17 AM
Suprachoroidal Delivery of Investigational Gene Therapy Surabgene Lomparvovec (Sura-vec, ABBV-RGX-314): Results in NPDR at 2.5 Years	David Boyer, MD	11:17 AM	11:20 AM
Adrenaline vs Tranexamic Acid for Intraoperative Hemostasis in PDR Vitrectomy: A Randomized Trial	SHISHIR VERGHESE, MS, FVRS, FAICO (Retina)	11:20 AM	11:23 AM
<b>Fellows Forum Award Winner:</b> Multiomic analysis of human diabetic retinal disease reveals severity and region-specific impairment of the retinal neurovascular unit	Rachana Haliyur, MD, PhD	11:23 AM	11:26 AM
Discussion		11:26 AM	11:41 AM
<i>Transition</i>		11:41 AM	11:43 AM

<b>Retinal Vascular Disease Symposium. Retinal Vascular Occlusions: Treatment Strategies, Outcomes, and Emerging Approaches</b>		11:43 AM	12:21 PM
Tiespectus (MK-8748) for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: Phase 1/2a Rioja Clinical Study	Baruch Kuppermann, MD, PhD, FASRS	11:43 AM	11:46 AM
Retinal Vein Occlusion with Good Baseline Visual Acuity: Immediate Treatment vs. Initial Observation	Ajay Kuriyan, MD, MS	11:46 AM	11:49 AM
Impact of Baseline Central Retinal Thickness on Visual and Anatomic Outcomes in Macular Edema Following RVO: A QUASAR Post hoc analysis through Wk 36	Ehsan Rahimy, MD	11:49 AM	11:52 AM
Discussion		11:52 AM	12:02 PM
Outcomes after low-IOP vitrectomy combined with arteriovenous sheathotomy, ILM peeling with a brief induced IOP fluctuation in Central Retinal Artery Occlusion	Subhendu Boral, MBBS, MD(AIIMS), DNB, FASRS (USA)	12:02 PM	12:05 PM
Clinical Outcomes of Switching Back to Intravitreal Bevacizumab Therapy	Mary Gao, DO	12:05 PM	12:08 PM
Detecting retrolubar emboli with orbital ultrasonography to predict neovascular glaucoma in central retinal artery occlusion	Erik Massenzio, MD	12:08 PM	12:11 PM
Discussion		12:11 PM	12:21 PM
General Lunch + Fellowship Directors Section Lunch		12:21 PM	1:36 PM
<b>Socioeconomics/Practice Management Panel. Health Systems and Equity in Retina Care</b>		1:36 PM	2:06 PM
Impact of Social Deprivation and Vulnerability on Patients With DME: Results From ELEVATUM and YOSEMITE/RHINE	Mohsin Ali, MD		
Baseline Biomarker Levels in Underrepresented Patients With DME: A Post Hoc Exploratory Analysis of ELEVATUM	Adrienne Scott, MD, FASRS		
Real-World Impact of Step Therapy Requirements on Access to Faricimab and Treatment Burden	Sabin Dang, MD		
Impact of Loss of Good Days Copay Assistance Program on Clinical and Anatomical Outcomes of Retinal Disease	Danny Mammo, MD		
Impact of Good Days Underfunding on Treatment Patterns and Outcomes in Patients with Neovascular Age-Related Macular Degeneration	Abdullah Abou-Samra, MD		
Discussion			
Transition		2:06 PM	2:08 PM
<b>Policy Panel</b>		2:08 PM	2:38 PM
Transition		2:38 PM	2:40 PM
<b>Socioeconomics/Practice Management Symposium. Health Disparities in Retina Care: Policy, Geography, and Population Outcomes</b>		2:40 PM	3:18 PM
Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee for Service: Comparison of Medicaid vs Medicare Reimbursement Rates for Vitreoretinal Surgeries in the United States	Ravi Parikh, MD MPH	2:40 PM	2:43 PM
Diabetic Retinopathy Outcomes Among Unhoused Individuals: A Big Data Analysis	Ella Leung, MD	2:43 PM	2:46 PM
Discussion	Judy Kim, MD, FARVO, FASRS	2:46 PM	2:49 PM
Impact of Geographic and Socioeconomic Factors on Endophthalmitis Presentation and Outcomes		2:49 PM	2:59 PM
Access to Pediatric Retina Care by Geographic Distribution and US Population Demographic Characteristics in 2025	Bivek Wagle, MD	2:59 PM	3:02 PM
The effects of Social and Demographic Factors on Severity of Inherited Retinal Diseases at the Time of Genetic Testing	Hong-Uyen Hua, MD	3:02 PM	3:05 PM
Discussion	Milam Brantley, MD, PhD	3:05 PM	3:08 PM
Transition		3:08 PM	3:18 PM
Panel Discussion: Impact of Vitrectomy on Light Adjustable Lenses Before Final Laser Lock-in in Post-Cataract Surgery Patients		3:18 PM	3:20 PM
Break	Osama Sabbagh, MD	3:20 PM	3:30 PM
<b>Pediatric Retina - The Michael Trese Symposium in Pediatric Retina</b>		3:30 PM	4:10 PM
ICROP3 Zone I Definition Varies with Post Menstrual Age and is Not Consistent with Type 1 ETROP Treatment Zone I Definition	Darius Moshfeghi, MD, FASRS	4:10 PM	4:13 PM
Tele-screening is associated with reduced treatment rates in a large cohort of infants at risk for retinopathy of prematurity.	Eugenia Greig, MD	4:13 PM	4:16 PM
Retinopathy of Prematurity in Infants Born at 22 Weeks of Gestational Age	Sahal Saleh, MD	4:16 PM	4:19 PM
Discussion		4:19 PM	4:29 PM
Atypical regression patterns of Retinopathy of Prematurity, post combined therapy with intravitreal Anti-VEGF and laser photocoagulation.	Bibhuti Kashyap, MD, FACS, DNB, FRCSEd, FRCS (GLASGOW), FICO	4:29 PM	4:32 PM
Outcomes of a combined surgical approach for stage 5 ROP: A prospective interventional case series	Sameera Nayak, MBBS, MS, FRCS	4:32 PM	4:35 PM
Choroidal Vasculature Index and Choroidal Area in Stage 3+ ROP Eyes Treated With Anti-VEGF With or Without Laser	Swati Agarwal-Sinha, MD, FASRS	4:35 PM	4:38 PM
Comparative Axial Elongation Rates in High Myopia With and Without Retinopathy of Prematurity	Melissa Yuan, MD	4:38 PM	4:41 PM
Discussion		4:41 PM	4:53 PM
Transition		4:53 PM	4:55 PM
<b>MacTel Panel. Macular Telangiectasia Type 2: Imaging, Emerging Therapies, and Clinical Outcomes</b>		4:55 PM	5:25 PM
Ellipsoid Zone Area Loss Is an Independent Predictor of Reduced Fixation Stability in Macular Telangiectasia Type 2	Eleonora Lad, MD, PhD		
Longitudinal Multimodal Imaging and Clinical Outcomes in Individuals Who Received Revakinagene Tarorectel-lwey Encapsulated Cell Therapy for MacTel	Lydia Sauer, MD		
Reading Speed Outcomes in Macular Telangiectasia Type 2: Sham-Control Data From the Phase 3 Revakinagene Tarorectel-lwey (NT-501) Trials	Dean Elliott, MD		

Surgical-Related Adverse Events With Revakinagene Tarorecelwey in Macular Telangiectasia Type 2: A Root Cause Analysis	W. Clark, MD, FASRS		
Misdiagnosis of Macular Telangiectasia Type 2 in the Era of Neuroprotective Therapy	Robin Vora, MD		
Discussion			
Transition		5:25 PM	5:30 PM
WinR Case Conference		5:30 PM	7:15 PM
FIT & Resident Reception		6:00 PM	8:00 PM
VIP Reception at Cirque Eloize			
<b>Saturday, July 18</b>			
<b>Empowerment &amp; Opportunity Mentoring Breakfast</b>			
<b>Experience Center (Fellows &amp; Residents)</b>		6:30 AM	7:30 AM
<b>Continental Breakfast</b>		7:15 AM	8:15 AM
<b>Retinal Detachment Panel. Retinal Detachment: PVR Prevention, Surgical Outcomes, and Risk Factors</b>		8:00 AM	8:20 AM
Statin Use and Association with Proliferative Vitreoretinopathy and Reoperation Risk Following Retinal Detachment Surgery	Christina Weng, MD, MBA, FASRS		
Trends in Centralization of Urgent Versus Elective Vitreoretinal Surgery in the Medicare Fee-For-Service Population: 2017-2023	Stephanie Engelhard, MD		
Interim Report #2 of the FIXER - Methotrexate Trial (Prevention of Proliferative Vitreoretinopathy with Intravitreal Methotrexate in Primary Retinal Detachment Repair)	Christopher Riemann, MD		
Discussion			
Transition		8:20 AM	8:22 AM
<b>Retinal Detachment Symposium 1. Retinal Detachment: Risk Stratification, Prophylaxis, and Imaging Insights</b>		8:22 AM	8:46 AM
Retinopathy prophylaxis of lattice degeneration in fellow eyes after rhegmatogenous detachment: results from a large national database	Ahmed Shakarchi, MD, MPH	8:22 AM	8:25 AM
Retinopathy Prophylaxis for Lattice Degeneration Without Retinal Breaks: A Large Retrospective Cohort Study	Ahmed Sallam, MD PhD FRCOphth	8:25 AM	8:28 AM
Outer Retinal Corrugations Indicate Retinal Break Status in Rhegmatogenous Retinal Detachment	Jeffrey Mah, MD	8:28 AM	8:31 AM
Outer Retinal Corrugation Biomechanics Predict Outer Retinal Folds and Visual Acuity in Rhegmatogenous Retinal Detachment	Isabela Martins Melo, MD	8:31 AM	8:34 AM
Discussion		8:34 AM	8:46 AM
Transition		8:46 AM	8:48 AM
<b>Hereditary Retinal Disease &amp; Genetics Panel. Stargardt Disease: Emerging Therapies, Biomarkers, and Clinical Trial Design</b>		8:48 AM	9:13 AM
Results of the Phase 3 DRAGON Trial of Tinlarebant (LBS-008) for Stargardt Disease (STGD1)	Paul Bernstein, MD, PhD		
Oral Gildeuretinol for Slowing Stargardt Disease Progression: Safety and Efficacy Data from the Phase 2 TEASE Study and Follow-up Phase 3 Study Design	Christine Kay, MD		
Relationship of Three Atrophy Growth Rate Metrics with Lesion Shape Factors in Stargardt Disease: Implications for Clinical Trial Design	Liangbo Shen, MD		
Automated Quantification of Decreased FAF in Stargardt Disease Using Starguard: Validation Against Manual Grading Standards	Jia-Horung Hung, MD, PhD		
Discussion			
Transition		9:13 AM	9:15 AM
<b>Best of JVRD and Journal Updates</b>		9:15 AM	9:30 AM
Transition		9:30 AM	9:32 AM
Break		9:32 AM	10:12 AM
<b>Pharmacology Symposium. Balancing Risk and Benefit: Pharmacologic Safety in Retina Care</b>		10:12 AM	10:36 AM
Association of Peri-Event Anti-VEGF with Mortality and Sequelae Following Stroke or Myocardial Infarction	Darius Bordbar, MD	10:12 AM	10:15 AM
Safety of Continuing Anti-VEGF Therapy Around the Time of Nonophthalmic Incisional Surgery: A Multisite Matched Cohort Study	Odetta Houghton, MD	10:15 AM	10:18 AM
'Drop less Vitrectomy' with 'Suprachoroidal Trimoxil' for epiretinal membranes: A Comparative Analysis of Safety and Efficacy with standard of care topi	K. Chalam, MD, PhD, MBA, FRCS(C), FASRS	10:18 AM	10:21 AM
A Pilot Study Evaluating Safety and Patient Comfort of a Compounded Povidone-Iodine and Proparacaine Combination	Ivan Suñer, MD, MBA	10:21 AM	10:24 AM
Discussion		10:24 AM	10:36 AM
Transition		10:36 AM	10:38 AM
<b>AMD - Non-neovascular Symposium 3. Geographic Atrophy: Functional Outcomes, Treatment Response, and Predictive Biomarkers</b>		10:38 AM	10:57 AM
Structure-Function Link of the Ellipsoid Zone and Low Luminance Deficit in Geographic Atrophy with Monthly and Every-Other-Month Avacincaptad Pegol	Rachel Downes, MD	10:38 AM	10:41 AM
Pegcetacoplan versus Avacincaptad pegol: Efficacy of Treatment in the Same Eye	Josh Walsh	10:41 AM	10:44 AM
Baseline Characteristics Associated With Loss of BCVA $\geq$ 15 ETDRS Letters in Participants With Geographic Atrophy in the Phase 2 ARCHER Study	Margaret Chang, MD, MS	10:44 AM	10:47 AM
Discussion		10:47 AM	10:57 AM
Transition		10:57 AM	10:59 AM

<b>Real-World Retina: Outcomes, Complications, and Risk Stratification</b>		<b>10:59 AM</b>	<b>11:37 AM</b>
Incidence, prevalence and risk factors for pathologic myopia and associated complications: a multi-center database study	Michael Floutsos, MD	10:59 AM	11:02 AM
Incidence and risk factors of retinal tear and detachment after YAG capsulotomy: an IRIS® Registry (Intelligent Research in Sight) analysis	Jordan Deaner, MD	11:02 AM	11:05 AM
Ten-Year Real-World Outcomes of Intravitreal Antibiotics Alone, Deferred Vitrectomy, and Immediate Vitrectomy for Acute Post-Cataract Endophthalmitis	Aditya Kelkar, MS, FRCS, FASRS, FRCOphth	11:05 AM	11:08 AM
Discussion		11:08 AM	11:18 AM
Endophthalmitis Following Pars Plana Vitrectomy: An IRIS® Registry Study	Matthew Starr, MD, FASRS	11:18 AM	11:21 AM
Proliferative Vitreoretinopathy in Contemporary Retinal Detachment Surgery: Socioeconomic, Surgical, and Ocular Determinants in the IRIS® Registry	Leo Kim, MD, PhD	11:21 AM	11:24 AM
Discussion		11:27 AM	11:37 AM
Transition		11:37 AM	11:39 AM
<b>Macular Holes &amp; Macular Pucker Panel 2. Macular Surgery Complications: Outcomes After Vitrectomy for Hole and Pucker</b>		<b>11:39 AM</b>	<b>12:04 PM</b>
epiretinal membrane removal	Libby Wei, MD		
Photocoagulation for Lattice Degeneration	Marta Stevanovic, MD, MSc		
Phacovitrectomy versus Sequential Surgery for Macular	Charles Zhang, MD		
Traction Maculopathy: Incidence, Risk Factors, and Outcomes	Taku Wakabayashi, MD, PhD		
Discussion			
General Lunch + WinR Lunch		<b>12:04 PM</b>	<b>1:19 PM</b>
<b>Retinaws</b>		<b>1:19 PM</b>	<b>2:19 PM</b>
Transition		2:19 PM	2:21 PM
<b>Ocular Oncology Symposium. Uveal Melanoma: From Biopsy to Biomarkers to Clinical Decision-Making</b>		<b>2:21 PM</b>	<b>2:51 PM</b>
Viscous Fluid Control Assisted Fine-Needle Aspiration Biopsy for Uveal Melanoma: Surgical Technique	Gordon Crabtree, MD	2:21 PM	2:24 PM
Gene Expression Profiling for Uveal Melanoma: The first decade and beyond defines best care for our patients	Timothy Murray, MD, MBA, FASRS	2:24 PM	2:27 PM
Limits of Mutation Profiling as a Predictor of 15-GEF/PRAPE Risk in Uveal Melanoma	David Reichstein, MD	2:27 PM	2:30 PM
Clinicopathologic characteristics, gene expression, and metastatic risk of uveal melanomas with no uveal melanoma-associated mutations (no UMAMs)	Amy Scheffler, MD FACS FASRS	2:30 PM	2:33 PM
Prophylactic bevacizumab after Plaque Brachytherapy in high-risk posterior uveal melanoma: Impact on development of radiation retinopathy	Prithvi Mruthyunjaya, MD, MHS	2:33 PM	2:36 PM
Discussion		2:36 PM	2:51 PM
Break		<b>2:51 PM</b>	<b>3:31 PM</b>
<b>Best of Business of Retina</b>		<b>3:31 PM</b>	<b>3:46 PM</b>
Transition		3:46 PM	3:48 PM
<b>Creative Awards</b>		<b>3:48 PM</b>	<b>4:13 PM</b>
Transition		4:13 PM	4:15 PM
<b>Diabetic Retinopathy Panel 2. Diabetic Retinopathy: Outcomes and Predictors</b>		<b>4:15 PM</b>	<b>4:40 PM</b>
Impact of Baseline Subretinal Fluid on Treatment Outcomes in DME: Analysis of the Phase 3 YOSEMITE and RHINE Trials	Rolake Alabi, MD PhD		
Baseline Macular Vascular Status Determines Perfusion and Visual Recovery After Panretinal Photocoagulation in Severe Diabetic Retinopathy Without Macular Edema	Eoi Jong Seo, MD, PhD		
Assessment of Intraretinal Cyst Turbidity on Optical Coherence Tomography: Clinical Implications in DME From YOSEMITE/RHINE	Andreas Pollreis, MD		
The Association Between Diabetic Retinopathy Severity and Dementia Risk	Manju Subramanian, MD		
Discussion			
Transition		4:40 PM	4:42 PM
<b>Retinal Detachment Symposium 2. Beyond Routine RD: Complex Cases, AI Prediction, and Surgical Decision-Making</b>		<b>4:42 PM</b>	<b>5:06 PM</b>
Predicting the Location of Retinal Tears in Eyes with Rhegmatogenous Retinal Detachment Using Artificial Intelligence	John Thompson, MD	4:42 PM	4:45 PM
Clinical features of retinal detachment (RD) following prophylactic retinopexy in children with Stickler syndrome: implications for optimal treatment and management	Franco Recchia, MD	4:45 PM	4:48 PM
Colobomatous Retinal Detachments: A Single Center Retrospective Analysis	Amer Alsoudi, MD	4:48 PM	4:51 PM
Scleral Buckle Revision in the Vitrectomy Era	Irmak Karaca, MD, FEBO, FICO, MRCSEd	4:51 PM	4:54 PM
Discussion		4:54 PM	5:06 PM
Closing Reception: Marche Bonsecours		<b>6:00 PM</b>	